Comments
Jubilant Life Sciences today posted a consolidated net loss of Rs 94.11 crore for the second quarter ended September 30, 2014. The company had posted a net loss of Rs 80.58 crore during the same period of previous fiscal.
Its net sales for the September quarter stood at Rs 1,362.11 crore during the period, down 4.36 per cent compared to Rs 1,424.3 crore in the same period previous fiscal.
Jubilant Life Sciences, Chairman and Managing Director, Shyam S Bhartia said: “The company’s performance in the quarter was affected mainly due to the continued impact of US FDA Warning letter on Spokane facility and adverse price impact on account of new capacities and regulatory changes in China in Advanced Intermediates business.”
Overall expenses of the company went up by 7.56 per cent to Rs 1,329.29 crore in Q2 of FY’15 against Rs 1,235.75 crore in the Q2 of FY’14.
During the quarter, revenue of pharmaceuticals segment declined 11.34 per cent to Rs 614.30 crore, while revenue from life science ingredients segment went up by 1.67 per cent to Rs 756.8 crore.
For the half year ended September 30, 2014, the company posted a net loss of Rs 89.33 crore as against net loss of Rs 133.20 crore in the year ago period.
Net sales of the company for the half year ended September 30, 2014, rose to Rs 2,822.64 crore compared to Rs 2,742.34 crore in same period previous fiscal.
Shares of Jubilant Life Sciences closed at Rs 164.85, up 1.13% per cent from their previous close on BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.